Real-world persistence with fingolimod for the treatment of multiple sclerosis: a systematic review and meta-analysis
D Kantor, K Johnson, MC Vieira, J Signorovitch… - Journal of the …, 2018 - Elsevier
Objective To systematically review reports of fingolimod persistence in the treatment of
relapsing-remitting multiple sclerosis (RRMS) across data sources and practice settings, and …
relapsing-remitting multiple sclerosis (RRMS) across data sources and practice settings, and …
Handling related publications reporting real-world evidence in network meta-analysis: a case study in multiple sclerosis
M Betts, K Fahrbach, B Neupane… - Journal of …, 2023 - becarispublishing.com
Aim: The presence of two or more publications that report on overlapping patient cohorts
poses a challenge for quantitatively synthesizing real-world evidence (RWE) studies. Thus …
poses a challenge for quantitatively synthesizing real-world evidence (RWE) studies. Thus …
[PDF][PDF] Improving Outcomes and Resource Use in Multiple Sclerosis: What are the Benefits Associated With an Early Treatment Strategy With Fingolimod?
J Carrasco, D Viriato, J Fonseca… - Rev Port …, 2016 - researchgate.net
Improving Outcomes and Resource Use in Multiple Sclerosis: What are the Benefits Associated
With an Early Treatment Strategy Wit Page 1 Improving Outcomes and Resource Use in Multiple …
With an Early Treatment Strategy Wit Page 1 Improving Outcomes and Resource Use in Multiple …
Otimizar os Resultados ea Utilização de Recursos no Tratamento da Esclerose Múltipla: Quais são os Benefícios Associados a uma Estratégia de Tratamento …
J Carrasco, D Viriato, J Fonseca… - Revista …, 2016 - revista.farmacoterapia.pt
Otimizar os Resultados ea Utilização de Recursos no Tratamento da Esclerose Múltipla: Quais
são os Benefícios Associados a uma Estratégia de Tratamento Precoce com Fingolimod …
são os Benefícios Associados a uma Estratégia de Tratamento Precoce com Fingolimod …